Terms: = Bone cancer AND MYH9, P35579, 4627, ENSG00000100345, DFNA17 AND Treatment
4 results:
1. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
Elife; 2021 Jun; 10():. PubMed ID: 34059198
[TBL] [Abstract] [Full Text] [Related]
2. Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (myh9).
Zhang H; Liu S; Tang L; Ge J; Lu X
Bioengineered; 2021 Dec; 12(1):162-171. PubMed ID: 33356805
[TBL] [Abstract] [Full Text] [Related]
3. Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Rodeghiero F; Pecci A; Balduini CL
J Thromb Haemost; 2018 Sep; 16(9):1700-1710. PubMed ID: 29956472
[TBL] [Abstract] [Full Text] [Related]
4. Clinic, pathogenic mechanisms and drug testing of two inherited thrombocytopenias, ANKRD26-related Thrombocytopenia and myh9-related diseases.
Balduini A; Raslova H; Di Buduo CA; Donada A; Ballmaier M; Germeshausen M; Balduini CL
Eur J Med Genet; 2018 Nov; 61(11):715-722. PubMed ID: 29545013
[TBL] [Abstract] [Full Text] [Related]
